Observational study on the acquisition of immunity in convalescent people with Novel Coronavirus(COVID-19) infection

Observational study on the acquisition of immunity in convalescent people with SARS-CoV-2(COVID-19) infection - SARS-CoV-2 observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044638

Enrollment

100

Registered

2021-06-24

Start date

2021-06-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2 infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Specimens from non-hospitalized convalescent patients with SARS-CoV-2 infection and specimens from hospitalized convalescent patients with SARS-CoV-2 infection (1)Specimens for which the research subject's free written consent to participate in this research has been obtained. (2)Specimens from research subjects who have consented to the collection of information on such diagnosis and treatment to medical institutions and health centers that have diagnosed and treated SARS-CoV-2 infection. (3)Specimens from research subjects who are 20 years old or older at the time of consent. (4)Specimens from research subjects who have recovered from infection after testing positive for SARS-CoV-2 in a nucleic acid detection test or antigen test and have tested negative in a nucleic acid detection test or antigen test, or stored specimens from persons who have recovered from infection similar to the former. (5)Specimens received after 20 days but before 180 days from the date of the test that tested positive for SARS-CoV-2 (6)For stored specimens,specimens with a residual of 300uL(serum)or more.

Exclusion criteria

Exclusion criteria: (1)Specimens from unrecovered SARS-CoV-2 infected individuals. (2)Specimens from COVID-19 prophylactic vaccine recipients. (3)Specimens from research subjects who have requested to withdraw consent. (4) Specimens that the principal investigator or sub-investigator determines to be ineligible.

Design outcomes

Primary

Measure	Time frame
(1) Neutralizing activity of SARS-CoV-2 against Pseudovirus in convalescent patients with SARS-CoV-2 infection (2)SARS-CoV-2 spike (S) glycoprotein specific antibody titer in convalescent patients with SARS-CoV-2 infection	—

Countries

Japan

Contacts

Public ContactMasaaki Akutagawa

EPS Corporation Clinical Development Business Division Monitoring Center

akutagawa.masaaki763@eps.co.jp070-6697-4084

Outcome results